Pharmaceutical and Biotech

Parmaceutical companies strive for superior patient experiences by providing increasingly complex therapies in complex regulatory environment. Virtual twin experiences have become, the enabler for digital transformation in risk, change and complexity management for Life Sciences companies.
 
Improved quality and regulatory intelligence, along with data-driven, model-based innovation from drug to processes to supply chain design delivers novel therapies faster and at lower cost without compromising quality.
 
The goal is to create an integrated framework for end-to-end compliance, embedding quality and regulatory best practices and product traceability from patient to lab.

Life Sciences organizations that digitalize to collaborate and to build the ability to learn and fail fast across the entire innovation continuum will win in the marketplace. 

Open innovation, collaborative research, outsourced clinical trials and manufacturing all accelerate the delivery of differentiated patient experiences. 

Digital enablers transform the way your organization innovates and operates, driving significantly enhanced margins with patient centric experiences and increased productivity and profits.

Complex diseases, pandemic risk, competition as well as new business models for connected and personalized therapies which will be reimbursed based on value, require the wholesale transformation of Product Supply and Operations.

More flexible plants, leveraging data, single use and modular equipment deliver novel therapies at lower cost - both financial as well as environmental and make novel therapies accessible and affordable globally.

Such agile manufacturing technologies require the mastering of processes, tech-transfer and scale-up as well as Quality by Design. This, and the ability to intelligently use the vast amounts of data and leverage sophisticated virtual twin experiences supporting scientists, engineers and operators delivers fast, accurate and at low cost - right first time.